1. Scrip
  2. >>Business

Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory

FY25: 5-10 Product Approvals Expected In US

 
• By Vibha Ravi

Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal

Strategy
Torrent Spells Out Its Acquisition, Licensing Strategy • Source: Shutterstock

Torrent Pharmaceuticals Ltd. executives recently commented on their acquisition strategy and expectations even as speculation around deals for Indian companies like JB Chemicals & Pharmaceuticals Ltd. and Bharat Serums And Vaccines Limited (BSV) were doing the rounds, with Torrent also in the mix of rumored bidders.

Last evening, Mankind Pharma Ltd. bought out 100% of BSV for an enterprise value of about INR136.3bn ($1.6bn). (Also see "Podcast: Amid Talk Of KKR Stake Sale, JB CEO Stresses Business As Usual" - Scrip, 4 June, 2024

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business